دورية أكاديمية
أعرض في EDS

Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.
المؤلفون: Segalés L; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain., Juanpere N; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Department of Pathology, Hospital del Mar, Barcelona, Spain., Gallarín N; Hospital del Mar Research Institute, Barcelona, Spain., Lorenzo M; Department of Pathology, Hospital del Mar, Barcelona, Spain., López D; Department of Pathology, Hospital del Mar, Barcelona, Spain., Perera-Bel J; Hospital del Mar Research Institute, Barcelona, Spain., Rodriguez-Vida A; Hospital del Mar Research Institute, Barcelona, Spain.; Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain., Fumadó L; Department of Urology, Hospital del Mar, Barcelona, Spain., Cecchini L; Department of Urology, Hospital del Mar, Barcelona, Spain., Bellmunt J; Hospital del Mar Research Institute, Barcelona, Spain.; Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lloreta-Trull J; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.; Department of Pathology, Hospital del Mar, Barcelona, Spain., Hernández-Llodrà S; Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain. silvia.hernandez@upf.edu.
المصدر: Virchows Archiv : an international journal of pathology [Virchows Arch] 2024 Aug; Vol. 485 (2), pp. 281-290. Date of Electronic Publication: 2023 Nov 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer International Country of Publication: Germany NLM ID: 9423843 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-2307 (Electronic) Linking ISSN: 09456317 NLM ISO Abbreviation: Virchows Arch Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin ; New York : Springer International, c1994-
مواضيع طبية MeSH: Prostatic Neoplasms*/pathology , Prostatic Neoplasms*/metabolism , Prostatic Neoplasms*/diagnosis , Biomarkers, Tumor*/analysis , Immunohistochemistry*, Humans ; Male ; Aged ; Middle Aged ; Prognosis ; PTEN Phosphohydrolase/analysis ; PTEN Phosphohydrolase/metabolism ; Transcriptional Regulator ERG/analysis ; Transcriptional Regulator ERG/metabolism ; Repressor Proteins/analysis ; Repressor Proteins/metabolism ; Transcription Factors/analysis ; Transcription Factors/metabolism ; Antigens, Neoplasm/analysis ; Antigens, Neoplasm/metabolism ; Membrane Transport Proteins ; DNA-Binding Proteins/analysis ; DNA-Binding Proteins/metabolism ; Nuclear Proteins/analysis ; Nuclear Proteins/metabolism ; Monosaccharide Transport Proteins
مستخلص: The impact of tumor focality on prostate cancer (PCa) prognosis has been addressed in several studies with conflicting results. Tumor foci from multifocal (MF) PCa can show highly heterogeneous molecular features. Our aim was to analyze the protein expression of PTEN, SPOP, SLC45A3, ETV1, ERG and the "triple hit" (ERG overexpression, PTEN plus SLC45A3 loss) in unifocal (UF) and MF PCa, to evaluate their value as prognostic markers according to focality, and the role of tumor heterogeneity in MF disease. PTEN, SPOP, SLC45A3, ETV1 and ERG immunohistochemical expression was evaluated in 185 PCa from 9 TMAs, 51 UF and 134 MF. In a subset of 69 MF cases, the dominant and secondary foci (DF and SF) were compared. Heterogeneity was considered when both tumor foci presented different expression patterns. Relationship with clinicopathological features was also analyzed. MF PCa was diagnosed in significantly younger patients when compared to UF ones (p = 0.007). ETV1 overexpression was associated with UF disease (p = 0.028). A shorter time to PSA recurrence was related to SLC45A3 wt expression in UF PCa (p = 0.052), and to SPOP expression loss (p = 0.043) or "triple hit" phenotype in MF PCa (p = 0.041). In MF cases, PTEN loss, SLC45A3 loss and "triple hit" phenotype were associated with the DF and had significant heterogeneity. In conclusion, our results indicate that UF and MF PCa have relevant and consistent molecular differences. The analysis of an immunohistochemical panel, composed by PTEN, SPOP, SLC45A3, ETV1 and ERG, could be useful to predict outcome in MF cases.
(© 2023. The Author(s).)
References: Oncotarget. 2017 May 26;8(43):74106-74118. (PMID: 29088771)
Pathobiology. 2018;85(1-2):108-116. (PMID: 29393241)
Genes (Basel). 2020 Nov 25;11(12):. (PMID: 33255593)
Prostate. 2021 Dec;81(16):1267-1277. (PMID: 34533858)
Diagn Pathol. 2019 Jan 12;14(1):2. (PMID: 30636627)
J Clin Invest. 2021 May 17;131(10):. (PMID: 33998599)
Transl Oncol. 2022 Feb;16:101311. (PMID: 34902740)
Eur Urol. 2019 Mar;75(3):498-505. (PMID: 30181068)
J Urol. 2009 Dec;182(6):2689-94. (PMID: 19836800)
EMBO J. 2021 Sep 15;40(18):e108389. (PMID: 34459009)
Hum Pathol. 2010 Jun;41(6):781-93. (PMID: 20466122)
Prostate. 2015 Aug 1;75(11):1216-26. (PMID: 25939480)
Nat Rev Urol. 2018 Apr;15(4):222-234. (PMID: 29460925)
Nat Genet. 2009 May;41(5):619-24. (PMID: 19396168)
Gastroenterology. 2021 Apr;160(5):1853-1855. (PMID: 33316233)
Nat Genet. 2015 Jul;47(7):736-45. (PMID: 26005866)
Prostate. 2021 Jul;81(10):703-709. (PMID: 33956350)
Ther Adv Urol. 2012 Aug;4(4):155-60. (PMID: 22852025)
BJU Int. 2020 Jul;126(1):26-54. (PMID: 32306543)
JCI Insight. 2019 Jan 24;4(2):. (PMID: 30674724)
Prostate Cancer Prostatic Dis. 2020 Sep;23(3):494-506. (PMID: 32071439)
Nat Rev Urol. 2021 Feb;18(2):79-92. (PMID: 33328650)
Am J Surg Pathol. 2007 Jun;31(6):882-8. (PMID: 17527075)
Curr Oncol Rep. 2018 Jun 1;20(8):58. (PMID: 29858674)
Nat Rev Urol. 2009 Aug;6(8):429-39. (PMID: 19657377)
Mod Pathol. 2013 Mar;26(3):435-47. (PMID: 23018874)
Prostate Cancer Prostatic Dis. 2013 Jun;16(2):132-8. (PMID: 23381693)
J Thorac Oncol. 2017 Sep;12(9):1398-1402. (PMID: 28583587)
Clin Transl Oncol. 2020 May;22(5):694-702. (PMID: 31359337)
Virchows Arch. 2014 May;464(5):589-94. (PMID: 24619626)
Med Sci Monit. 2009 Feb;15(2):BR61-63. (PMID: 19179963)
Transl Oncol. 2019 Jan;12(1):43-48. (PMID: 30265975)
JCI Insight. 2018 Nov 2;3(21):. (PMID: 30385730)
Semin Cancer Biol. 2015 Apr;31:111-8. (PMID: 25066860)
Nat Rev Urol. 2018 Oct;15(10):627-642. (PMID: 30065357)
J Urol. 2011 Aug;186(2):506-10. (PMID: 21679993)
Cancer Cell Int. 2018 Nov 12;18:177. (PMID: 30459527)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)
Int J Mol Sci. 2013 Jun 03;14(6):11816-29. (PMID: 23736690)
Prostate. 2016 Jun;76(9):854-65. (PMID: 26959281)
Prostate. 2020 Jan;80(1):38-50. (PMID: 31584209)
Prostate. 2012 May 15;72(7):762-8. (PMID: 21882214)
Virchows Arch. 2019 Oct;475(4):457-466. (PMID: 31016435)
Eur Urol Oncol. 2021 Jun;4(3):358-369. (PMID: 33888445)
Int Braz J Urol. 2018 Jan-Feb;44(1):14-21. (PMID: 29039897)
Int J Cancer. 2020 Jun 15;146(12):3369-3378. (PMID: 32159858)
Cell Rep Med. 2022 Apr 19;3(4):100604. (PMID: 35492239)
Nat Rev Clin Oncol. 2011 Jan;8(1):48-55. (PMID: 21116296)
معلومات مُعتمدة: FIS/Instituto Carlos III/FEDER PI15/00452 Instituto de Salud Carlos III
فهرسة مساهمة: Keywords: Focality; Heterogeneity; Immunohistochemical panel; Prognosis; Prostate cancer
المشرفين على المادة: 0 (Biomarkers, Tumor)
0 (SPOP protein, human)
EC 3.1.3.67 (PTEN Phosphohydrolase)
0 (Transcriptional Regulator ERG)
0 (SLC45a3 protein, human)
0 (ERG protein, human)
EC 3.1.3.67 (PTEN protein, human)
0 (Repressor Proteins)
0 (Transcription Factors)
0 (Antigens, Neoplasm)
0 (Membrane Transport Proteins)
0 (ETV1 protein, human)
0 (DNA-Binding Proteins)
0 (Nuclear Proteins)
0 (Monosaccharide Transport Proteins)
تواريخ الأحداث: Date Created: 20231128 Date Completed: 20240816 Latest Revision: 20240819
رمز التحديث: 20240819
مُعرف محوري في PubMed: PMC11329545
DOI: 10.1007/s00428-023-03699-z
PMID: 38017230
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-2307
DOI:10.1007/s00428-023-03699-z